annb0t
Top 20
ResMed RMD continues to see growth in patient diagnosis trends in sleep apnea, COPD and asthma. Yet, we are worried about the stiff competition faced by ResMed. The stock carries a Zacks Rank #3 (Hold).
In the past year, ResMed has outperformed its industry. The stock has lost 18.7% compared with the 51.7% decline of the industry.
ResMed exited the second quarter of fiscal 2023 with better-than-expected earnings and revenues. The company recorded a robust sales performance in the quarter on in...
>>> Read more: ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers
In the past year, ResMed has outperformed its industry. The stock has lost 18.7% compared with the 51.7% decline of the industry.
ResMed exited the second quarter of fiscal 2023 with better-than-expected earnings and revenues. The company recorded a robust sales performance in the quarter on in...
>>> Read more: ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers
